Nanogen Issued Patent for Electronic Devices for Active Biological Operations

May 05, 2004, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN),
 developer of molecular and point-of-care diagnostic products, announced today
 that it was issued U.S. Patent No. 6,726,880, "Electronic Devices for
 Performing Active Biological Operations and Method of Using Same," by the U.S.
 Patent and Trademark Office. The '880 patent relates to new devices that
 enable increased sensitivity of active, programmable electronic matrix (APEX)
 devices and perform actions such as concentration and assembly of biological
 materials on a substrate.
     DNA, RNA, proteins and other biologics can be electronically concentrated
 at collection electrodes and then re-distributed to reaction or detection
 electrodes. With alternating manipulation of the collection and reactive
 electrodes, molecular nanostructures can be assembled for more sensitive
 detection or used to manufacture molecular structures such as DNA hybrids or
 Protein/Protein complexes. With the addition of the '880 patent, Nanogen now
 has 59 issued patents in the United States.
     "The '880 patent builds upon and extends our previous programmable
 electronic matrix patents by describing approaches to the collection and
 concentration of biological materials that can then be manipulated in an
 organized manner," said Howard C. Birndorf, Nanogen chairman and chief
 executive officer. "Nanogen continues to add to its intellectual property
 position in order to retain the value of our novel technologies and their
 potential applications."
     About Nanogen
     Nanogen, Inc. develops and commercializes products for the molecular and
 point-of-care diagnostics markets. The company seeks to establish the unique,
 open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R)
 Cartridge as the standard platform for the prediction, diagnosis and treatment
 of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents
 and related products to research and clinical reference labs for the
 development of tests for the detection of genetic mutations associated with a
 variety of diseases, such as cystic fibrosis, Alzheimer's disease, and
 cardiovascular disease. The company's ten years of research involving
 nanotechnology may also have future applications in medical diagnostics,
 biowarfare and other industries. Nanogen's business unit, SynX Pharma,
 leverages proteomic and biomarker research to offer a line of point-of-care
 diagnostic tests. For additional information please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 Nanogen's NanoChip(R) System can be successfully further commercialized,
 whether other products under development can be successfully developed and
 commercialized, whether results reported by our customers or partners can be
 identically replicated, whether ASRs currently sold by Nanogen will become
 FDA-approved molecular diagnostic test kits, whether Nanogen will be
 successful in developing additional ASRs and protocols utilizing the
 NanoChip(R) System, and other risks and uncertainties discussed under the
 caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K
 for the year ended December 31, 2003 filed with the Securities and Exchange
 Commission. These forward-looking statements speak only as of the date hereof.
 Nanogen disclaims any intent or obligation to update these forward-looking

SOURCE Nanogen, Inc.